Mundipharma has signed a multi-year agreement for up to $600m with Kolon Life Sciences to secure the exclusive rights for Invossa osteoarthritis therapy in Japan.
Mundipharma has signed a multi-year agreement for up to $600m with Kolon Life Sciences to secure the exclusive rights for Invossa osteoarthritis therapy in Japan.